Gossamer Bio, Inc.
GOSS
Rank in Stocks
#21609
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Share Price
$10.65
Last synced: 2026-11-09
Market Cap
$65.05M
Change (1 day)
8.96%
Change (1 year)
311.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gossamer Bio, Inc. (GOSS)
Category
Healthcare
Operating Margin for Gossamer Bio, Inc. (GOSS)
Operating Margin as of November 2026 TTM: -311.70%
According to Gossamer Bio, Inc.'s latest financial reports, its current operating margin (TTM) is -311.70%. At the end of 2025 the company had an operating margin of -336.81%.
Operating Margin history for Gossamer Bio, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -311.70% | -7.46% |
| 2025 | -336.81% | 544.74% |
| 2024 | -52.24% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.52% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Gossamer Bio, Inc.'s operating margin
What is Gossamer Bio, Inc.'s operating margin?
Gossamer Bio, Inc.'s operating margin is -311.70%, as of Nov 2026.
What was Gossamer Bio, Inc.'s operating margin in 2025?
In 2025, Gossamer Bio, Inc.'s operating margin was -336.81%, compared with -52.24% in 2024.
How has Gossamer Bio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Gossamer Bio, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-336.81%).
How does Gossamer Bio, Inc.'s operating margin compare with similar companies?
Gossamer Bio, Inc.'s operating margin (-311.70%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.